Dianthus Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell DNTH and other ETFs, options, and stocks.About DNTH
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies.
CEOMarino Garcia
CEOMarino Garcia
Employees78
Employees78
HeadquartersNew York, New York
HeadquartersNew York, New York
Founded2015
Founded2015
Employees78
Employees78
DNTH Key Statistics
Market cap2.28B
Market cap2.28B
Price-Earnings ratio-12.85
Price-Earnings ratio-12.85
Dividend yield—
Dividend yield—
Average volume739.12K
Average volume739.12K
High today$46.59
High today$46.59
Low today$43.79
Low today$43.79
Open price$44.88
Open price$44.88
Volume1.24M
Volume1.24M
52 Week high$46.59
52 Week high$46.59
52 Week low$13.37
52 Week low$13.37
Stock Snapshot
Dianthus Therapeutics(DNTH) stock is priced at $45.88, giving the company a market capitalization of 2.28B. It carries a P/E multiple of -12.85.
During the trading session on 2026-01-14, Dianthus Therapeutics(DNTH) shares reached a daily high of $46.59 and a low of $43.79. At a current price of $45.88, the stock is +4.8% higher than the low and still -1.5% under the high.
Trading volume for Dianthus Therapeutics(DNTH) stock has reached 1.24M, versus its average volume of 739.12K.
The stock's 52-week range extends from a low of $13.37 to a high of $46.59.
The stock's 52-week range extends from a low of $13.37 to a high of $46.59.
Analyst ratings
100%
of 15 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own DNTH. This list is generated using Robinhood data, and it’s not a recommendation.